Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 231,044,740 papers from all fields of science
Search
Sign In
Create Free Account
desloratadine
Known as:
8-chloro-6,11-dihydro-11-(4-Piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
, desloratadine [Chemical/Ingredient]
, 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
Expand
A long-acting piperidine derivate with selective H1 antihistaminergic and non-sedating properties. Desloratadine diminishes the typical histaminergic…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
16 relations
Broader (3)
Cholinergic Antagonists
Histamine H1 Antagonists, Non-Sedating
Loratadine
Narrower (2)
Clarinex
SCH 34117
Desloratadine:MCnc:Pt:Bld:Qn
Desloratadine:MCnc:Pt:Ser/Plas:Qn
Desloratadine:MCnc:Pt:Urine:Qn
Drug Allergy
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Structural characterization of in vitro rat liver microsomal metabolites of antihistamine desloratadine using LTQ-Orbitrap hybrid mass spectrometer in combination with online hydrogen/deuterium…
Guodong Chen
,
Ibrahim Daaro
,
B. Pramanik
,
J. Piwinski
Journal of Mass Spectrometry
2009
Corpus ID: 39258798
In vitro drug metabolism study is an integral part of drug discovery process. In this report, we have described the application…
Expand
Review
2009
Review
2009
Chronic urticaria: do urticaria nonexperts implement treatment guidelines? A survey of adherence to published guidelines by nonexperts
M. Ferrer
,
I. Jáuregui
,
+6 authors
J. Sastre
British Journal of Dermatology
2009
Corpus ID: 35452346
Background Guidelines including level of evidence and grade of recommendation were recently published for chronic urticaria (CU…
Expand
2009
2009
Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients
M. Augustin
,
S. Ehrle
Journal of the European Academy of Dermatology…
2009
Corpus ID: 1894005
Background Post‐marketing surveillance studies (PMSS) of medications are often mandated by authorities, provide crucial insights…
Expand
Highly Cited
2007
Highly Cited
2007
Response normalized liquid chromatography nanospray ionization mass spectrometry
R. Ramanathan
,
Ruyun Zhong
,
N. Blumenkrantz
,
S. Chowdhury
,
K. Alton
Journal of the American Society for Mass…
2007
Corpus ID: 10829705
2007
2007
Selective inhibition of Kir currents by antihistamines.
Bo-yi Liu
,
Zhanfeng Jia
,
+4 authors
Hailin Zhang
European Journal of Pharmacology
2007
Corpus ID: 13391841
2005
2005
Increased nasal airflow with budesonide compared with desloratadine during the allergy season.
S. Bhatia
,
F. Baroody
,
M. Detineo
,
R. Naclerio
Archives of Otolaryngology - Head and Neck…
2005
Corpus ID: 39108325
OBJECTIVE To compare the effects of desloratadine, an H1-blocking antihistamine, and budesonide, an intranasal corticosteroid, on…
Expand
Review
2005
Review
2005
Histamine-mediated mechanisms in the human nasal airway.
T. Taylor-Clark
,
J. Foreman
Current opinion in pharmacology (Print)
2005
Corpus ID: 32910464
Review
2004
Review
2004
Current concepts and therapeutic strategies forallergic rhinitis in school-age children
M. Blaiss
2004
Corpus ID: 72800438
2003
2003
Studies on performance and sleepiness with the H1-antihistamine, desloratadine.
A. Nicholson
,
Alison D F Handford
,
C. Turner
,
B. Stone
Aviation Space and Environmental Medicine
2003
Corpus ID: 12240199
INTRODUCTION The purpose of this study was to establish whether the H1-antihistamine desloratadine (5 mg), the active metabolite…
Expand
2001
2001
Applications of new liquid chromatography-tandem mass spectrometry technologies for drug development support.
L. Yang
,
N. Wu
,
P. Rudewicz
Journal of Chromatography A
2001
Corpus ID: 25779223
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE